Remove Clinical Trials Remove Drug Development Remove Therapies
article thumbnail

A third of clinical trials cancelled during Phase II

Drug Discovery World

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.

article thumbnail

Biologic CAR T cell engager approved for UK clinical trial

Drug Discovery World

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T cell therapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The curative potential of CAR-T cell therapy

Drug Discovery World

NS: Vittoria’s lead programme, VIPER-101, targeting T-cell lymphoma, reached a significant milestone with the acceptance of our Investigational New Drug (IND) application in October 2023. Beyond VIPER-101, we’re developing subsequent programmes for autoimmune disease and solid tumours.

Therapies 147
article thumbnail

The need for greater diversity in clinical trials  

Drug Discovery World

By Lucy Radley , Senior Vice President, Head of European Regulatory Development at ProPharma Group. Clinical trials are, undoubtedly, an essential part of the drug development process, providing us with valuable information about the safety and efficacy of new treatments and therapies.

article thumbnail

How to advance AAV-based gene therapies

Drug Discovery World

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies.

Therapies 162
article thumbnail

Including Patients with Borderline Personality Disorder in Clinical Trials

Conversations in Drug Development Trends

Over the past two decades, industry-sponsored clinical trials have targeted treatments for BPD, yielding some promising outcomes; however, broader psychiatric research often excludes BPD patients, a trend that extends to the emerging field of psychedelic studies.

article thumbnail

What can patients do to give input into clinical trial design? 

Drug Discovery World

If anything, this period has been a reminder that people are the primary reason we do what we do, and the Patient Access, Healthcare & People track at Advanced Therapies Europe 2022 allowed DDW’s Multimedia Editor Megan Thomas to share several reflections on the topic. . Never before was the whole world a potential patient.